Mereo BioPharma Group plc

NASDAQ:MREO

Biotechnology

Healthcare
$0.32 +9.69%

+$0.03 today

Market cap
$51.08M
Beta
0.28
P/E (TTM)
-1.4
EPS (TTM)
-$0.22
52W Low $0.20High $3.05

Volume 1.26M

Average 3.36M

MREO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Mereo BioPharma Group plcNASDAQ: MREO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $4.02M fell 44.7% year over year, behind the -28.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.

Context

  • Selling, general & admin amounted to 4601.6% of revenue in FY2025.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $17.85M (-22.4%) for the fiscal year ending Dec 2026, a slowdown from the -13.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.02M-4.2% QoQ
Last fiscal yearDec 2025
$23.01M-13.0% YoY
LTMMar 2026
$19.76M-28.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.7%+540.8%+585.6 pp
1 year-13.0%-22.4%-9.4 pp
3-year CAGR-0.2%+58.7%+59.0 pp
5-year CAGR+106.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
23.01M USD
Year-over-year change
-13.0%
4-year CAGR
+1.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MREO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -28.1% is the lowest of 10, against a peer median of +18.2%.
  • Selling, general & admin amounts to 3951.0% of revenue for MREO, versus a peer median of 239.4%.
MREO Competitors
Selling, General & Admin for MREO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$1.14T USD+9732467.6%-14.5%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$37.43M USD+18.7%+65.2%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$35.46M USD-13.0%+55.9%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$26.76M USD+58.7%+29.7%—
SLNSilence Therapeutics plcLTM Mar 2026$23.59M USD—+2.2%2560.2%
CADLCandel Therapeutics, Inc.LTM Mar 2026$20.1M USD+39.9%+8.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M USD-28.1%-0.2%3951.0%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$17.4M USD+18.2%+41.6%—
PRQRProQR Therapeutics N.V.LTM Mar 2026€14.33M EUR+6.6%-8.9%106.6%
ACIUAC Immune S.A.LTM Mar 2026CHF 11.38M CHF+4.4%+6.7%307.5%
IMMPImmutep LimitedFY2025A$8.64M AUD-2.4%+6.2%171.4%
Peer median (excluding MREO) —+18.2%+7.4%239.4%

Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.21M010M0500K
Cost of Revenue24.17M(257.44K)2.57M1.09M133K
Gross Profit25.04M257.44K7.43M(1.09M)367K
Gross Margin50.9%—74.3%—73.4%
Research & Development31.8M30.75M17.42M20.93M17.77M
Selling, General & Admin21.5M23.18M18.42M26.43M23.01M
Operating Expenses53.3M53.92M35.84M47.36M38.62M
Depreciation & Amortization866.47K895.5K1.06M1.09M1.15M
EBITDA25.49M(39.98M)(26.06M)(40.8M)(40.47M)
EBITDA Margin51.8%—-260.6%—-8094.8%
Operating Income(28.26M)(53.67M)(28.42M)(47.36M)(38.26M)
Operating Margin-57.4%—-284.2%—-7651.4%
Interest Income1.38K696K2.13M3.04M2.17M
Interest Expense5.22M3.36M2.88M1.37M255K
Other Income / Expenses47.48M9.21M(1.58M)4.11M(3.62M)
Income Before Tax19.22M(44.46M)(30M)(43.25M)(41.88M)
Pre-Tax Margin39.1%—-300.0%—-8375.6%
Income Tax Expense2.05M(2.34M)(532K)00
Net Income17.17M(42.12M)(29.47M)(43.25M)(41.88M)
Net Margin34.9%—-294.7%—-8375.6%
EPS (Basic)749.65(1,750.35)(1,100.22)(0.29)(0.26)
EPS (Diluted)749.65(1,750.35)(1,100.22)(0.29)(0.26)
Weighted Avg Shares116.73M120.64M131.89M147.92M159.42M
Weighted Avg Shares (Diluted)116.73M120.64M131.89M147.92M159.42M

Mereo BioPharma Group plc

NASDAQ:MREO

Intrinsic Alpha fair value

Locked

Current Price

$0.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.